Five Prime cuts 41 jobs, days be­fore pre­sent­ing da­ta at AS­CO meet­ing of GI can­cers

Things have not been the same at can­cer-fo­cused drug de­vel­op­er Five Prime Ther­a­peu­tics $FPRX since late 2017, when its Bris­tol-My­ers $BMY part­nered drug cabi­ral­izum­ab in com­bi­na­tion with Op­di­vo showed signs of weak ef­fi­ca­cy and a trou­bling safe­ty pro­file in an ear­ly-stage pan­cre­at­ic can­cer tri­al. On Tues­day, the com­pa­ny said it had cut 41 jobs to fo­cus its re­sources on its late-stage pipeline.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.